Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multimodal Analgesia Effect on Post Surgical Patient

Trial Profile

Multimodal Analgesia Effect on Post Surgical Patient

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gabapentin (Primary) ; Gabapentin (Primary) ; Paracetamol (Primary) ; Paracetamol (Primary) ; Bupivacaine; Cyclobenzaprine; Hydrocodone; Hydromorphone; Lorazepam; Morphine; Ondansetron; Oxycodone; Scopolamine
  • Indications Postoperative pain
  • Focus Therapeutic Use

Most Recent Events

  • 21 Mar 2025 Status changed from recruiting to completed.
  • 11 Mar 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2025.
  • 11 Mar 2022 Planned primary completion date changed from 30 Nov 2021 to 30 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top